Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Bonelli, RM; Hofmann, P.
A review of the treatment options for Huntington's disease.
EXPERT OPIN PHARMACOTHER. 2004; 5(4): 767-776.
Doi: 10.1517/14656566.5.4.767
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Bonelli Raphael
- Co-Autor*innen der Med Uni Graz
- Hofmann Peter
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Huntington's disease (HD) is an autosomal dominant, inherited, neuropsychiatric disease which gives rise to progressive motor, cognitive and behavioural symptoms. Its core pathology involves degeneration of the basal ganglia, in particular, the caudate and putamen, and is caused by a single autosomal gene coding for a mutated form of the protein, huntingtin. At the present time, the only treatment options available in HD are symptomatic. There are several substances available today for the treatment of chorea. Other neurological symptoms, such as dystonia, can be treated, but treatment is associated with a high risk of adverse events. Psychiatric symptoms, on the other hand, are often amenable to treatment and relief of these symptoms may provide significant improvement in quality of life.
- Find related publications in this database (using NLM MeSH Indexing)
- Antipsychotic Agents - therapeutic use
- Clinical Trials - therapeutic use
- Humans - therapeutic use
- Huntington Disease - drug therapy
- Movement Disorders - therapy
- Neuroprotective Agents - therapeutic use
- Psychotic Disorders - therapy
- Find related publications in this database (Keywords)
- aggression
- apathy
- chorea
- dystonia
- depression
- Huntington's disease
- psychosis
- treatment